Aerpio pharmaceuticals, inc. (ARPO)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
License revenue, and other

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Research and development

9,067

12,824

15,943

17,445

19,410

17,852

0

0

0

-

10,360

10,899

-

11,367

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Formation costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

General and administrative

8,787

9,756

11,835

12,951

13,293

13,485

0

0

0

-

8,045

7,494

-

5,265

9,801

8,541

7,073

5,861

23

23

23

23

22

22

22

22

23

23

22

22

22

22

23

23

19

19

0

0

0

Restructuring (benefit) expense

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restructuring expense

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

19,717

24,444

28,655

31,312

32,703

31,338

28,759

25,891

24,105

21,388

18,405

18,394

17,187

16,633

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-19,717

-24,444

-28,653

-12,488

-12,545

-11,181

-8,603

-24,558

-24,105

-21,388

-18,405

-18,394

-17,187

-16,633

-30,801

-26,060

-21,688

-17,486

-23

-23

-23

-23

-22

-22

-22

-22

-23

-23

-22

-22

-22

-22

-23

-23

-19

-19

0

0

0

Grant income

207

142

105

0

0

-

0

-

-

-

108

88

-

131

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

814

1,030

1,210

1,304

1,060

778

0

0

0

-

-387

-613

-

-482

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income

1,021

1,173

1,310

1,330

1,081

784

490

258

275

-12

-278

-525

-596

-349

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

7

7

6

6

6

6

5

5

5

5

4

4

4

3

3

3

2

0

0

0

Net and comprehensive loss

-18,696

-23,270

-27,342

-11,157

-11,463

-10,396

-8,113

-24,300

-23,830

-21,400

-18,683

-18,919

-17,784

-16,983

-30,516

-25,637

-21,259

-17,070

-31

-31

-30

-30

-28

-28

-28

-28

-28

-28

-28

-27

-26

-26

-27

-27

-23

-22

0

0

0

Net and comprehensive loss per share
Net and comprehensive loss

-18,696

-23,270

-27,342

-11,157

-11,463

-10,396

-8,113

-24,300

-23,830

-21,400

-18,683

-18,919

-17,784

-16,983

-30,516

-25,637

-21,259

-17,070

-31

-31

-30

-30

-28

-28

-28

-28

-28

-28

-28

-27

-26

-26

-27

-27

-23

-22

0

0

0

Extinguishment of preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Adjustment of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

943

1,997

3,052

4,080

4,152

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-10,396

-

-

-

-22,343

-20,681

-21,972

-21,641

-20,912

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted

-0.10

-0.11

-0.11

-0.14

-0.21

-0.21

0.28

-0.22

-0.27

0.41

-0.17

-0.21

-1.06

-4.46

-6.69

-6.30

-7.07

-31.14

0.00

0.00

0.00

-0.01

0.00

0.00

0.00

-0.01

0.00

0.00

0.00

-0.01

0.00

0.00

0.00

-0.01

0.00

0.00

0.00

0.00

0.00

Weighted average number of common shares used in computing net and comprehensive loss per share
Basic

40,588

-

40,588

-

40,588

-

40,527

-

-

-

26,926

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

40,588

-

40,588

-

40,588

-

40,961

-

-

-

26,926

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of common shares used in computing net loss per share attributable to common stockholders, basic and diluted

-

40,588

-

40,588

-

-

-

27,340

27,045

-

-

26,895

5,605

962

888

823

737

-12,762

5,000

5,000

5,000

5,000

5,000

5,000

5,000

5,000

5,000

5,000

5,000

5,000

5,000

5,000

5,000

-

5,000

5,000

-

-

-

Weighted-average number of common shares outstanding (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,000

5,000

5,000